IONS insider ownership: who sold, why, and what they still hold

What stands out

Two insiders sold $8.4M with no disclosed plan: Brett Monia ($5.2M) and Joan Herman ($3.2M). The filings don't state a reason.Brett Monia: largest such sale, Jan 30, 2026 · Joan Herman: largest such sale, Nov 19, 2025

Michael Hayden bought 20K shares for $1.1M, first on Jul 30, 2026.Purchase, Jul 30, 2026

A share of stake is shown for 0 of the 19 officers and directors who sold. 23 are left out

Left out: Brett Monia, Spencer Berthelsen, Joseph Wender, Elizabeth Hougen, Frank Bennett, Richard Geary, Lynne Parshall, Brian Birchler, Michael Hayden, Patrick O'Neil, Eugene Schneider, Joan Herman, Joseph Loscalzo, Joseph Baroldi, Eric Swayze, Allene Diaz, Joseph Klein III, Shannon Devers, Kyle Jenne, Holly Kordasiewicz, Michael Yang, Peter Reikes and Ludwig Hantson (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Brett Monia

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$30.3M72% planned, 11% to cover taxes 17% no plan disclosed

Elizabeth Hougen

EVP, Finance & CFO

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$17.9M91% planned, 5% to cover taxes 3% no plan disclosed

Frank Bennett

EVP, Chief Scientific Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$16.7M93% planned, 4% to cover taxes 3% no plan disclosed

Richard Geary

EVP, Chief Development Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$9.5MDisclosed plan

Shannon Devers

EVP, Chief Human Resources Ofc

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$8.7M93% planned, 7% to cover taxes

All 19 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Jul 31, 2026Michael Hayden bought 5K shares ($258K).

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Michael Hayden Director	5,000	$51.60	n/a	n/a	Jul 31, 2026	Jul 31, 2026

Common questions

Is the Ionis Pharmaceuticals Inc CEO selling stock?

Yes. Brett Monia sold 387K shares ($30.3M) in the past 12 months, 72% of it under a trading plan disclosed in the filings.

Why are Ionis Pharmaceuticals Inc insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 84% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 8% were to cover taxes and 9% had no disclosed plan. A trading plan schedules sales in advance.

Are any Ionis Pharmaceuticals Inc insiders buying?

Yes. 1 officer or director reported 2 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold19 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Brett Monia Chief Executive Officer, Director	$30.3M 387K shares	Not confirmed share of stake is being verified. Why	72% under a disclosed plan, 11% to cover taxes 17% no plan disclosed
Elizabeth Hougen EVP, Finance & CFO	$17.9M 245K shares	Not confirmed share of stake is being verified. Why	91% under a disclosed plan, 5% to cover taxes 3% no plan disclosed
Frank Bennett EVP, Chief Scientific Officer	$16.7M 206K shares	Not confirmed share of stake is being verified. Why	93% under a disclosed plan, 4% to cover taxes 3% no plan disclosed
Richard Geary EVP, Chief Development Officer	$9.5M 126K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Shannon Devers EVP, Chief Human Resources Ofc	$8.7M 107K shares	Not confirmed share of stake is being verified. Why	93% under a disclosed plan, 7% to cover taxes
Joseph Loscalzo Director	$7.1M 94K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Joseph Klein III Director	$6.0M 77K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Eric Swayze EVP Research	$5.2M 66K shares	Not confirmed share of stake is being verified. Why	76% under a disclosed plan, 14% to cover taxes 10% no plan disclosed
Allene Diaz Director	$5.2M 65K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Holly Kordasiewicz EVP, Chief Development Officer	$4.8M 65K shares	Not confirmed share of stake is being verified. Why	93% under a disclosed plan, 7% to cover taxes
Joseph Wender Director	$4.3M 56K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Eugene Schneider EVP, Chf Clinical Develop Ofcr	$3.7M 47K shares	Not confirmed share of stake is being verified. Why	67% under a disclosed plan, 19% to cover taxes 14% no plan disclosed
Brian Birchler EVP, Corp and Development Ops	$3.6M 48K shares	Not confirmed share of stake is being verified. Why	66% under a disclosed plan, 20% to cover taxes 14% no plan disclosed
Kyle Jenne EVP, Chf GL Pdt Str Ofcr	$3.3M 44K shares	Not confirmed share of stake is being verified. Why	85% under a disclosed plan, 15% to cover taxes
Joan Herman Director	$3.2M 44K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Joseph Baroldi EVP, Chief Business Officer	$2.6M 33K shares	Not confirmed share of stake is being verified. Why	43% under a disclosed plan, 40% to cover taxes 17% no plan disclosed
Patrick O'Neil EVP CLO & General Counsel	$2.2M 29K shares	Not confirmed share of stake is being verified. Why	45% under a disclosed plan, 31% to cover taxes 23% no plan disclosed
Spencer Berthelsen Director	$1.2M 16K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Lynne Parshall Director	$1.2M 15K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

The full ownership picture0 of 23 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Brett Monia

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Brett Monia are complete.

Chief Executive Officer, Director

n/a

−387K

n/a

Vesting, gifts, unvested awards and holding lines for Brett Monia

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Brett Monia are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
76,643	$37.58	Jan 2, 2033	$1.1M
116,580	$52.87	Jan 1, 2034	$0
86,263	$34.69	Jan 1, 2035	$1.5M
85,410	$79.67	Jan 1, 2036	$0
99,872	$56.78	Jan 3, 2028	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Spencer Berthelsen

Director

n/a

−16K

n/a

Vesting, gifts, unvested awards and holding lines for Spencer Berthelsen

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Spencer Berthelsen are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,111	$47.11	Jun 30, 2034	$45K
11,518	$39.94	Jun 30, 2035	$134K
5,369	$79.19	Jun 30, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Joseph Wender

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Joseph Wender are complete.

Director

n/a

−56K

n/a

Vesting, gifts, unvested awards and holding lines for Joseph Wender

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joseph Wender are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,111	$47.11	Jun 30, 2034	$45K
11,518	$39.94	Jun 30, 2035	$134K

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Elizabeth Hougen

EVP, Finance & CFO

n/a

−245K

n/a

Vesting, gifts, unvested awards and holding lines for Elizabeth Hougen

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Elizabeth Hougen are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,405	$37.58	Jan 2, 2033	$76K
43,200	$52.87	Jan 1, 2034	$0
31,000	$34.69	Jan 1, 2035	$524K
25,770	$79.67	Jan 1, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Frank Bennett

EVP, Chief Scientific Officer

n/a

−206K

n/a

Vesting, gifts, unvested awards and holding lines for Frank Bennett

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Frank Bennett are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,406	$32.60	Jan 2, 2032	$46K
27,200	$52.87	Jan 1, 2034	$0
22,000	$34.69	Jan 1, 2035	$372K
19,350	$79.67	Jan 1, 2036	$0
2,406	$32.60	Jan 2, 2032	$46K

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Richard Geary

EVP, Chief Development Officer

n/a

−126K

n/a

Vesting, gifts, unvested awards and holding lines for Richard Geary

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Richard Geary are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,200	$52.87	Jan 1, 2034	$0
22,000	$34.69	Jan 1, 2035	$372K

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Lynne Parshall

Director

n/a

−15K

n/a

Vesting, gifts, unvested awards and holding lines for Lynne Parshall

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lynne Parshall are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,111	$47.11	Jun 30, 2034	$45K
11,518	$39.94	Jun 30, 2035	$134K

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Brian Birchler

EVP, Corp and Development Ops

n/a

−48K

n/a

Vesting, gifts, unvested awards and holding lines for Brian Birchler

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Brian Birchler are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,482	$47.34	Jan 2, 2024	$66K
27,200	$52.87	Jan 1, 2034	$0
22,000	$34.69	Jan 1, 2035	$372K
19,350	$79.67	Jan 1, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Michael Hayden

Director

n/a

Vesting, gifts, unvested awards and holding lines for Michael Hayden

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Hayden are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,111	$47.11	Jun 30, 2034	$45K
11,518	$39.94	Jun 30, 2035	$134K
5,369	$79.19	Jun 30, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Patrick O'Neil

EVP CLO & General Counsel

n/a

−29K

n/a

Vesting, gifts, unvested awards and holding lines for Patrick O'Neil

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Patrick O'Neil are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
4,467	$32.60	Jan 2, 2032	$85K
8,942	$37.58	Jan 2, 2033	$125K
17,000	$52.87	Jan 1, 2034	$0
22,000	$34.69	Jan 1, 2035	$372K
19,350	$79.67	Jan 1, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Eugene Schneider

EVP, Chf Clinical Develop Ofcr

n/a

−47K

n/a

Vesting, gifts, unvested awards and holding lines for Eugene Schneider

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eugene Schneider are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
24,265	$32.60	Jan 2, 2032	$461K
27,200	$52.87	Jan 1, 2034	$0
22,000	$34.69	Jan 1, 2035	$372K
19,350	$79.67	Jan 1, 2036	$0
26,000	$60.89	Jan 1, 2027	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Joan Herman

Director

n/a

−44K

n/a

Vesting, gifts, unvested awards and holding lines for Joan Herman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joan Herman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,111	$47.11	Jun 30, 2034	$45K
11,518	$39.94	Jun 30, 2035	$134K
5,369	$79.19	Jun 30, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Joseph Loscalzo

Director

n/a

−94K

n/a

Vesting, gifts, unvested awards and holding lines for Joseph Loscalzo

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joseph Loscalzo are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,111	$47.11	Jun 30, 2034	$45K
11,518	$39.94	Jun 30, 2035	$134K
5,369	$79.19	Jun 30, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Joseph Baroldi

EVP, Chief Business Officer

n/a

−33K

n/a

Vesting, gifts, unvested awards and holding lines for Joseph Baroldi

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joseph Baroldi are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
26,700	$31.80	Jan 30, 2032	$529K
27,200	$52.87	Jan 1, 2034	$0
22,000	$34.69	Jan 1, 2035	$372K
19,350	$79.67	Jan 1, 2036	$0
3,500	$52.87	Jan 1, 2034	$0
2,500	$34.69	Jan 1, 2035	$42K
2,600	$79.67	Jan 1, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Eric Swayze

EVP Research

n/a

−66K

n/a

Vesting, gifts, unvested awards and holding lines for Eric Swayze

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eric Swayze are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,200	$52.87	Jan 1, 2034	$0
22,000	$34.69	Jan 1, 2035	$372K
4,065	$60.89	Jan 1, 2027	$0
19,350	$79.67	Jan 1, 2036	$0
154	$52.87	Jan 1, 2034	$0
163	$34.69	Jan 1, 2035	$3K
150	$79.67	Jan 1, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Allene Diaz

Director

n/a

−65K

n/a

Vesting, gifts, unvested awards and holding lines for Allene Diaz

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Allene Diaz are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
11,518	$39.94	Jun 30, 2035	$134K
5,369	$79.19	Jun 30, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Joseph Klein III

Director

n/a

−77K

n/a

Vesting, gifts, unvested awards and holding lines for Joseph Klein III

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joseph Klein III are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,369	$79.19	Jun 30, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Shannon Devers

EVP, Chief Human Resources Ofc

n/a

−107K

n/a

Vesting, gifts, unvested awards and holding lines for Shannon Devers

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Shannon Devers are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
928	$32.60	Jan 2, 2032	$18K
5,744	$37.58	Jan 2, 2033	$81K
16,042	$49.25	Jan 1, 2025	$38K
8,877	$52.87	Jan 1, 2034	$0
2,971	$56.78	Jan 3, 2028	$0
17,125	$60.89	Jan 1, 2027	$0
11,280	$40.85	Sep 28, 2034	$121K
16,500	$34.69	Jan 1, 2035	$279K
19,350	$79.67	Jan 1, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Kyle Jenne

EVP, Chf GL Pdt Str Ofcr

n/a

−44K

n/a

Vesting, gifts, unvested awards and holding lines for Kyle Jenne

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kyle Jenne are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
32,601	$46.10	Feb 25, 2034	$179K
14,025	$34.69	Jan 1, 2035	$237K
19,350	$79.67	Jan 1, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Holly Kordasiewicz

EVP, Chief Development Officer

n/a

−65K

n/a

Vesting, gifts, unvested awards and holding lines for Holly Kordasiewicz

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Holly Kordasiewicz are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$34.69	Jan 1, 2035	$169K
11,500	$37.58	Jan 2, 2033	$161K
19,800	$52.87	Jan 1, 2034	$0
16,600	$79.67	Jan 1, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Michael Yang

Director

n/a

Vesting, gifts, unvested awards and holding lines for Michael Yang

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Yang are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
12,356	$49.82	Dec 14, 2033	$22K
11,518	$39.94	Jun 30, 2035	$134K
5,369	$79.19	Jun 30, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Peter Reikes

Director

n/a

Vesting, gifts, unvested awards and holding lines for Peter Reikes

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Peter Reikes are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,753	$75.13	Jun 4, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Ludwig Hantson

Director

n/a

Vesting, gifts, unvested awards and holding lines for Ludwig Hantson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ludwig Hantson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,753	$75.13	Jun 4, 2036	$0

Estimate: options held × ($51.60 − strike price), using the most recent insider trade price on Form 4 (Jul 31, 2026), not a market close.

Holdings and share of stake for Ionis Pharmaceuticals Inc are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$137M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $137M across 1,769,640 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $114M · 84%

16%

The lighter segment is sales with no plan disclosed in the filing ($22.2M), including tax-related sales outside a plan.

No plan disclosed · $11.9M

Sales with no 10b5-1 plan and no tax reference in the filing. $5.2M of it is Brett Monia. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Brett Monia, Jan 30, 2026

Taxes

$10.4M of sales (7.6%) cite tax obligations in their footnotes, $93K of them also under a plan. Example: Kyle Jenne, Apr 16, 2026

Purchases · 1 buyer (2 trades)

1 officer or director bought shares in this period, in 2 trades(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 14 purchase trades.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Brett Monia Chief Executive Officer, Director	387K	$30.3M	72%	22%	Jan 16, 2026 to Jun 26, 2026
Elizabeth Hougen EVP, Finance & CFO	245K	$17.9M	91%	13%	Jan 16, 2026 to Mar 17, 2026
Frank Bennett EVP, Chief Scientific Officer	206K	$16.7M	93%	12%	Jan 16, 2026 to Jul 7, 2026
Richard Geary EVP, Chief Development Officer	126K	$9.5M	100%	7%	Oct 31, 2025 to Nov 6, 2025
Shannon Devers EVP, Chief Human Resources Ofc	107K	$8.7M	93%	6%	Oct 15, 2025 to Apr 2, 2026
Joseph Loscalzo Director	94K	$7.1M	100%	5%	Oct 31, 2025 to May 4, 2026
Joseph Klein III Director	77K	$6.0M	100%	4%	Nov 25, 2025 to Jul 1, 2026
Eric Swayze EVP Research	66K	$5.2M	76%	4%	Oct 16, 2025 to Jun 25, 2026
Allene Diaz Director	65K	$5.2M	100%	4%	Mar 3, 2026 to Jul 7, 2026
Holly Kordasiewicz EVP, Chief Development Officer	65K	$4.8M	93%	4%	Jan 16, 2026 to Jul 7, 2026
Joseph Wender Director	56K	$4.3M	100%	3%	Oct 30, 2025 to Dec 1, 2025
Eugene Schneider EVP, Chf Clinical Develop Ofcr	47K	$3.7M	67%	3%	Jan 16, 2026 to Jun 26, 2026
Brian Birchler EVP, Corp and Development Ops	48K	$3.6M	66%	3%	Oct 14, 2025 to Apr 16, 2026
Kyle Jenne EVP, Chf GL Pdt Str Ofcr	44K	$3.3M	85%	2%	Jan 16, 2026 to Apr 16, 2026
Joan Herman Director	44K	$3.2M	0%	2%	Nov 19, 2025 to Nov 19, 2025
Joseph Baroldi EVP, Chief Business Officer	33K	$2.6M	43%	2%	Jan 16, 2026 to Jun 26, 2026
Patrick O'Neil EVP CLO & General Counsel	29K	$2.2M	45%	2%	Jan 16, 2026 to Jun 26, 2026
Spencer Berthelsen Director	16K	$1.2M	100%	0.9%	Jun 1, 2026 to Jun 15, 2026
Lynne Parshall Director	15K	$1.2M	100%	0.8%	Oct 15, 2025 to Apr 15, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$12.6M	$12.6M	$4K	$0
Nov 2025	$8.8M	$5.7M	$0	$3.2M
Dec 2025	$2.3M	$2.3M	$0	$0
Jan 2026	$24.1M	$5.9M	$9.4M	$8.8M
Feb 2026	$11.3M	$11.3M	$0	$0
Mar 2026	$47.4M	$47.4M	$0	$0
Apr 2026	$3.5M	$2.6M	$860K	$0
May 2026	$6.9M	$6.9M	$0	$0
Jun 2026	$16.1M	$16.1M	$0	$0
Jul 2026	$3.5M	$3.5M	$0	$0
Aug 2026	$0	$0	$0	$0
Sep 2026	$0	$0	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 4x the 5-year average. 19 insiders sold; the average is 12 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	1.77M	19	$137M
Oct 13, 2025 1 year earlier	1.11M	16	$61.9M
Oct 13, 2024 2 years earlier	565K	14	$28.1M
Oct 14, 2023 3 years earlier	175K	13	$7.1M
Oct 14, 2022 4 years earlier	9.3K	4	$374K
Oct 14, 2021 5 years earlier	388K	11	$20.4M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty23 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Ionis Pharmaceuticals Inc are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology1,501 filings on record, 112 filed in the 12-month period, and how we read them

All 1,501 Forms 3, 4 and 5 on record for Ionis Pharmaceuticals Inc (SEC CIK 874015), filed from Sep 30, 2002 to Sep 2, 2026; 112 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages. 32 filings were left out because Ionis Pharmaceuticals Inc filed them as an owner of another company's stock. 37 older filings exist only on paper and could not be read.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (26)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Onaiza Cadoret-Manier	Sep 4, 2024	35,788 shares, last reported balance as of Feb 2, 2024
Frederick Muto	Jul 19, 2022	62,597 shares, last reported balance as of Jul 15, 2022
Stanley Crooke	Jan 28, 2021	1,325,546 shares, last reported balance as of Jan 26, 2021
Breaux Castleman	Jul 6, 2020	19,183 shares, last reported balance as of Jul 6, 2020
Damien McDevitt	Jul 17, 2019	2,573 shares, last reported balance as of Jul 15, 2019
Sarah Boyce	Jan 17, 2018	8,931 shares, last reported balance as of Jan 16, 2018
John Reed	Sep 6, 2012	No balance on record
Richard DiMarchi	Jul 2, 2010	No balance on record
David Ecker	Sep 3, 2008	38,631 shares, last reported balance as of Sep 2, 2008
Michael Treble	Aug 13, 2008	No balance on record
Jeffrey Jonas	Jan 4, 2008	No balance on record
Kleanthis Xanthopoulos	Dec 5, 2007	No balance on record
Mark Wedel	Jul 10, 2007	6,603 shares, last reported balance as of Jul 6, 2007
Arthur Levin	Apr 27, 2007	1,674 shares, last reported balance as of Apr 25, 2007
Richard Brown	Mar 9, 2006	2,348 shares, last reported balance as of Mar 8, 2006
LILLY ELI & CO	Aug 12, 2005	2,500,000 shares, last reported balance as of Aug 5, 2005
Christopher Gabrieli	Jul 6, 2005	156,171 shares, last reported balance as of May 14, 2004
Christopher Gabrieli	Jul 6, 2005	No balance on record
Patricia Lowenstam	Jan 4, 2005	850 shares, last reported balance as of Dec 9, 2004
John McNeil	Jan 4, 2005	No balance on record
Mark Skaletsky	Jul 2, 2004	No balance on record
Aron Stein	Jul 2, 2004	1,536 shares, last reported balance as of Jul 1, 2004
Hans De Haan	May 5, 2004	No balance on record
Karen Lundstedt	Mar 12, 2004	5,407 shares, last reported balance as of Mar 10, 2004
Douglas Cole	Mar 9, 2004	9,616 shares, last reported balance as of Mar 9, 2004
Jon Holmlund	Feb 11, 2004	13,103 shares, last reported balance as of Jan 1, 2004

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Ionis Pharmaceuticals Inc insiders sold $137M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Ionis Pharmaceuticals Inc CEO selling stock?

Why are Ionis Pharmaceuticals Inc insiders selling?

Are any Ionis Pharmaceuticals Inc insiders buying?

The evidence

No plan disclosed · $11.9M

Taxes

Purchases · 1 buyer (2 trades)

Sales by month